# Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer

> **NCT01494012** · PHASE1 · TERMINATED · sponsor: **Stanford University** · enrollment: 1 (actual)

## Conditions studied

- Recurrent Ovarian Epithelial Cancer
- Recurrent Ovarian Germ Cell Tumor
- Malignant Tumor of Peritoneum
- Stage IV Ovarian Epithelial Cancer
- Stage IV Ovarian Germ Cell Tumor

## Interventions

- **RADIATION:** stereotactic body radiation therapy
- **PROCEDURE:** positron emission tomography
- **PROCEDURE:** computed tomography
- **OTHER:** questionnaire administration
- **DRUG:** fludeoxyglucose F 18

## Key facts

- **NCT ID:** NCT01494012
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-04
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2017-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01494012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01494012, "Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01494012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*